With investors focused on the performance of large cap biotech companies and their third quarter earnings the early returns have, by and large, been positive. As a result, as we close the curtain on what has been an extremely turbulent capital market environment in October, biotech has emerged relatively unscathed and is poised to finish the year in good shape.